Saturday, 5 September 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

DISTRI-LAND CERT Stock Was Up By 9.62% On Tuesday

Loading stream...

(VIANEWS) - The Market ended the session with DISTRI-LAND CERT (DISL.BR) rising 9.62% to €228.00 on Tuesday while BEL 20 fell 0.12% to €3,845.42.

About DISTRI-LAND CERT

Immobiliere Distri-Land NV engages in the issuing and managing of real estate certificates. The company was incorporated in 1989 and is based in Sint-Jans-Molenbeek, Belgium. Immobiliere Distri-Land NV operates as a subsidiary of KBC Bank NV.

Earnings Per Share

As for profitability, DISTRI-LAND CERT has a trailing twelve months EPS of €7.55.

PE Ratio

DISTRI-LAND CERT has a trailing twelve months price to earnings ratio of 30.2. Meaning, the purchaser of the share is investing €30.2 for every euro of annual earnings.

Volume

Today's last reported volume for DISTRI-LAND CERT is 6 which is 100% above its average volume of 3.

More news about DISTRI-LAND CERT (DISL.BR).

Categories

stockMarket

Tags

Market-Close NowStock PriceClosesStock Market NowEnd of DayDISL.BRPrice UpMarket CloseStock Price UpDISTRI-LAND CERTStock MarketStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com